Showing results (1391-1400 of 1,518) with videos related to

Sort By:
Pageof 152
ESMO Open|November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trialH Borghaei, K J O'Byrne, L Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 5, 2023
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized StudyEverett E Vokes, Francoise Mornex, Ahmet Sezer, et al.
Veterinary Parasitology|April 2, 2014
Natural infection of the wild canid, Cerdocyon thous, with the piroplasmid Rangelia vitalii in BrazilJoão F Soares, Bruno Dall'Agnol, Francisco B Costa, et al.
Frontiers in Surgery|December 5, 2018
Impact on Patient Care of a Multidisciplinary Center Specializing in Colorectal and Pelvic ReconstructionAlejandra Vilanova-Sánchez, Carlos Albert Reck, Richard J Wood, et al.
The New England Journal of Medicine|October 4, 2018
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Aaron S Mansfield, Aleksandra Szczęsna, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialMartin Reck, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2023
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerH Borghaei, F de Marinis, D Dumoulin, et al.
ESMO Open|September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinomaM Kirchner, K Kluck, R Brandt, et al.
Danish Medical Journal|October 10, 2025
Delirium prevalence and screening in the Danish healthcare systemMarie O Collet, Martin Shultz, Eva Laerkner, et al.
ESMO Open|May 28, 2025
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trialM C Garassino, J Khalifa, M Reck, et al.
Pageof 152